Latest Blogs

Dec 03, 2019
ASCO's delegation to the AMA HOD invites all ASCO members to share their thoughts and concerns concerning issues affecting the practice of oncology, as your input directly impacts the delegation's work.
Dec 03, 2019
When a patient is looking for the word "cure," anything else, especially if vague, is not enough. "No evidence of disease" leaves room for doubt but, importantly, also room for hope.
Dec 02, 2019
Dr. Omid Etemadi describes the evolution of integrated cancer care in the Philippines. 
Nov 26, 2019
What does the future of immuno-oncology look like? Dr. Elizabeth A. Mittendorf invites you to be part of the conversation at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium in February.
Subscribe to this column

Matthew S. Katz, MD

Matthew S. Katz, MD, is the Medical Director of Radiation Oncology at Lowell General Hospital and a partner in Radiation Oncology Associates, PA. He is former Chair of the Communications Committee for the American Society for Radiation Oncology (ASTRO) and External Advisory Board member for Mayo Clinic Center for Social Media. He serves on ASCO's Social Media Working Group, ASTRO's Education Committee, and Massachusetts Medical Society's Communications Committee. His areas of prime interest are patient education and health empowerment. Follow Dr. Katz on Twitter @subatomicdoc.

Nov 15, 2018
During my career, pathologists have always been the “doctor’s doctor.” Why can't they be the "patient's doctor" as well?
Dec 06, 2017
Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for their work, and  to implement new findings for our patients.
Jul 12, 2017
Here are 10 reasons why we should look at postoperative radiation for regional melanoma.
Jul 19, 2016
Drug companies play a key role in improving cancer care, but financial toxicity for patients continues to worsen. Eternal vigilance is the price of liberty from excessive drug costs, and we have an ethical obligation to hold pharmaceutical companies accountable.
Apr 08, 2016
We have discussed risk, biology, and the importance of complete reporting. So how do we decide to actually use RNI?
Apr 04, 2016
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?

Pages